RxDoctor Payments DataLook up a doctor →

Brian Whitson, MD

Pulmonary Disease · Norman, OKNPI 1053355073

Payments from drug & device makers

$21,458in general payments, 2019–2025

Across 1,110 payments — averaging $19.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$4K
  • GSK$3K
  • Boehringer Ingelheim$2K
  • Genentech USA, Inc.$2K
  • Insmed, Inc.$2K
  • Sanofi$1K
  • plus $8K from 34 others

What the payments were for

  • Consulting fees$1,3506%
  • Food & beverage$19,78092%
  • Education$3282%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,458 in reported general payments places this provider in the 80th percentile of 133 pulmonary disease providers in Oklahoma.

See all pulmonary disease providers in Oklahoma

Medicare billing

Part B allowed, 2024
$132,845
Medicare patients
729
Services billed
2,896

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter913$686,129
OfevNintedanib Esylate19$244,606
Prolastin CAlpha-1-Proteinase Inhibitor41$222,163
Breztri AerosphereBudesonide/Glycopyr/Formoterol232$156,524
Fasenra PenBenralizumab27$152,746
Breo ElliptaFluticasone/Vilanterol104$58,182
Spiriva RespimatTiotropium Bromide43$34,991
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr47$25,036
XareltoRivaroxaban36$22,131
Combivent RespimatIpratropium/Albuterol Sulfate33$20,779
Stiolto RespimatTiotropium Br/Olodaterol Hcl38$20,399
EliquisApixaban24$18,564
Incruse ElliptaUmeclidinium Bromide34$17,183
Fluticasone-SalmeterolFluticasone Propion/Salmeterol72$15,613
Albuterol Sulfate HfaAlbuterol Sulfate437$12,789

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Arnuity Ellipta$2,561$794,8291,128 claims
Boehringer IngelheimOfev, Spiriva Respimat, Combivent Respimat, Stiolto Respimat$1,919$320,775133 claims
Grifols USA, LLCProlastin C$949$222,16341 claims
AstraZenecaBreztri Aerosphere, Symbicort$4,357$169,164286 claims
PfizerEliquis$280$18,56424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 133 pulmonary disease providers in Oklahoma.

Other pulmonary disease in Norman

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →